Home › NCT06265688
First In Human Study of CX-2051 in Advanced Solid Tumors
RecruitingPhase 1
An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Measurable disease per RECIST v1.1 * Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue * Additional inclusion criteria may apply Exclusion Criteria: * Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated * Known active central nervous system (CNS) involvement by malignancy * Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1 * Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload * Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1 * Elevated baseline laboratory values * Serious concurrent illness * Pregnant or breast feeding * Additional exclusion criteria may apply
About the study
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
What is being tested
- CX-2051 (drug)
- Bevacizumab (drug)
Sponsor: CytomX Therapeutics · Participants: 160 · Started: Apr 2, 2024
Contact the study team
- Karen Deane · Phone: 650-515-3185
Official record on ClinicalTrials.gov — NCT06265688
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.